{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:16Z","timestamp":1792194916214,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01 AG052460"],"award-info":[{"award-number":["U01 AG052460"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS097776"],"award-info":[{"award-number":["R01 NS097776"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R33 NS101167"],"award-info":[{"award-number":["R33 NS101167"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01 NS058158"],"award-info":[{"award-number":["U01 NS058158"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.biopha.2022.112646","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T19:17:43Z","timestamp":1643138263000},"page":"112646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models"],"prefix":"10.1016","volume":"147","author":[{"given":"Varun","family":"Rawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Banik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Amaradhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asheebo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashidharamurthy","family":"Taval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Dingledine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thota","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112646_bib1","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1021\/jm401431x","article-title":"Prostanoid receptor EP2 as a therapeutic target","volume":"57","author":"Ganesh","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112646_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/intimm\/dxz021","article-title":"Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases","volume":"31","author":"Tsuge","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2174\/1381612824666180327165604","article-title":"Signaling pathways in inflammation and anti-inflammatory therapies","volume":"24","author":"Yeung","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2022.112646_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728222.2019.1554056","article-title":"The COX-2\/prostanoid signaling cascades in seizure disorders","volume":"23","author":"Rojas","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2022.112646_bib5","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1021\/acschemneuro.9b00311","article-title":"Novel microglia cell line expressing the human EP2 receptor","volume":"10","author":"Rojas","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112646_bib6","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.1218498110","article-title":"Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112646_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.12.032","article-title":"Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus","volume":"76","author":"Jiang","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2022.112646_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuropharm.2015.01.017","article-title":"Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus","volume":"93","author":"Rojas","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.112646_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuropharm.2016.07.028","article-title":"Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats","volume":"110","author":"Rojas","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.112646_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1573395511666150707181414","article-title":"Inflammatory cyclooxygenase activity and PGE2 signaling in models of Alzheimer\u2019s disease","volume":"11","author":"Johansson","year":"2015","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.biopha.2022.112646_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI77487","article-title":"Prostaglandin signaling suppresses beneficial microglial function in Alzheimer\u2019s disease models","volume":"125","author":"Johansson","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.112646_bib12","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","article-title":"Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer\u2019s disease","volume":"25","author":"Liang","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112646_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-4-2","article-title":"Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein","volume":"4","author":"Jin","year":"2007","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2022.112646_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21437","article-title":"The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis","volume":"64","author":"Liang","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2022.112646_bib15","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.4049\/jimmunol.178.12.8138","article-title":"The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis","volume":"178","author":"Sheibanie","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1084\/jem.20051310","article-title":"Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis","volume":"203","author":"Honda","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2022.112646_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/labinvest.3700491","article-title":"Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors","volume":"87","author":"Kabashima","year":"2007","journal-title":"Lab Investig."},{"key":"10.1016\/j.biopha.2022.112646_bib18","doi-asserted-by":"crossref","first-page":"44169","DOI":"10.1038\/srep44169","article-title":"EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis","volume":"7","author":"Greaves","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112646_bib19","first-page":"1","article-title":"Inhibition of the prostaglandin EP2 receptor prevents long-term cognitive impairment in a model of systemic inflammation","volume":"8","author":"Jiang","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2022.112646_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.jid.5700547","article-title":"Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness","volume":"127","author":"Brouxhon","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.biopha.2022.112646_bib21","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1096\/fj.06-7581com","article-title":"EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1\/2 pathways","volume":"21","author":"Donnini","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2022.112646_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.112.200444","article-title":"Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation","volume":"344","author":"Jiang","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.112646_bib23","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1038\/sj.onc.1209694","article-title":"EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival","volume":"25","author":"Kamiyama","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.112646_bib24","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bph.14622","article-title":"Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth","volume":"176","author":"Qiu","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112646_bib25","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1038\/sj.onc.1209538","article-title":"Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development","volume":"25","author":"Sung","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.112646_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1471-4159.2002.01157.x","article-title":"Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent","volume":"83","author":"Montine","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112646_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0002-9440(10)62336-X","article-title":"Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity","volume":"166","author":"Shie","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.112646_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/glia.20220","article-title":"Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity","volume":"52","author":"Shie","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2022.112646_bib29","doi-asserted-by":"crossref","first-page":"32676","DOI":"10.1074\/jbc.M703087200","article-title":"Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo","volume":"282","author":"Hoshino","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112646_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI6579","article-title":"Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor","volume":"103","author":"Tilley","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.112646_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/5583","article-title":"Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor","volume":"5","author":"Kennedy","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112646_bib32","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1073\/pnas.1037343100","article-title":"An EP2 receptor-selective prostaglandin E2 agonist induces bone healing","volume":"100","author":"Paralkar","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112646_bib33","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/ar3460","article-title":"Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability","volume":"13","author":"Mitsui","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2022.112646_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1165\/rcmb.2014-0486OC","article-title":"Impaired E prostanoid2 expression and resistance to prostaglandin e2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease","volume":"54","author":"Cahill","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2022.112646_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/cea.12142","article-title":"Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells","volume":"43","author":"Kay","year":"2013","journal-title":"Clin. Exp. Allergy"},{"issue":"99\u2013107","key":"10.1016\/j.biopha.2022.112646_bib36","article-title":"Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta\/IL-1 type I receptor\/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Machado-Carvalho","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2004-0126OC","article-title":"Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity","volume":"32","author":"White","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2022.112646_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2005.10.037","article-title":"Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells","volume":"117","author":"Ying","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib39","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1021\/acs.jmedchem.9b01218","article-title":"Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models","volume":"63","author":"Amaradhi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112646_bib40","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1021\/jm5000672","article-title":"Lead optimization studies of cinnamic amide EP2 antagonists","volume":"57","author":"Ganesh","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112646_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0006-8993(03)03322-5","article-title":"Central moxonidine on salivary gland blood flow and cardiovascular responses to pilocarpine","volume":"987","author":"Moreira","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112646_bib42","first-page":"17","article-title":"Central muscarinic modulation of fetal blood pressure and heart rate","volume":"13","author":"Szeto","year":"1990","journal-title":"J. Dev. Physiol."},{"key":"10.1016\/j.biopha.2022.112646_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-3565(25)25944-4","article-title":"The pressor response of the cat to histamine and pilocarpine","volume":"131","author":"Trendelenburg","year":"1961","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.112646_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41374-018-0116-6","article-title":"The cofilin phosphatase slingshot homolog 1 restrains angiotensin II-induced vascular hypertrophy and fibrosis in vivo","volume":"99","author":"Williams","year":"2019","journal-title":"Lab Investig."},{"key":"10.1016\/j.biopha.2022.112646_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2019.02.011","article-title":"Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury","volume":"149","author":"Jiang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.112646_bib46","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1038\/s41598-017-09528-z","article-title":"Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype","volume":"7","author":"Kang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112646_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/acsptsci.0c00040","article-title":"Inhibiting the PGE2 receptor EP2 mitigates excitotoxicity and ischemic injury","volume":"3","author":"Li","year":"2020","journal-title":"ACS Pharmcol. Transl. Sci."},{"key":"10.1016\/j.biopha.2022.112646_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.02.010","article-title":"A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition","volume":"133","author":"Rojas","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2022.112646_bib49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/epi4.12409","article-title":"COX-2\/PGE2 axis regulates hippocampal BDNF\/TrkB signaling via EP2 receptor after prolonged seizures","volume":"5","author":"Yu","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.biopha.2022.112646_bib50","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1021\/acs.jmedchem.1c00816","article-title":"EP2 antagonists (2011-2021): a Decade\u2019s journey from discovery to therapeutics","volume":"64","author":"Sluter","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112646_bib51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaci.2018.05.036","article-title":"T cell-intrinsic prostaglandin E2-EP2\/EP4 signaling is critical in pathogenic TH17 cell-driven inflammation","volume":"143","author":"Lee","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2017.04.045","article-title":"Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis","volume":"141","author":"Robb","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112646_bib53","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/ncomms2684","article-title":"Prostaglandin E(2) promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase","volume":"4","author":"Yao","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.112646_bib54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.1968","article-title":"Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion","volume":"15","author":"Yao","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112646_bib55","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2353\/ajpath.2009.081099","article-title":"Rescue of impaired fracture healing in COX-2-\/- mice via activation of prostaglandin E2 receptor subtype 4","volume":"175","author":"Xie","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.112646_bib56","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1210\/endo.141.6.7518","article-title":"Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro","volume":"141","author":"Li","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.112646_bib57","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","article-title":"Prostaglandins in bone: bad cop, good cop?","volume":"21","author":"Blackwell","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.112646_bib58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00296289","article-title":"Effects of long-term daily administration of prostaglandin-E2 on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats","volume":"50","author":"Ke","year":"1992","journal-title":"Calcif. Tissue Int."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:47:16Z","timestamp":1760100436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"alternative-id":["S0753332222000348"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112646","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112646"}}